Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares traded down 4.4% during trading on Wednesday . The stock traded as low as $146.75 and last traded at $147.50, with a volume of 219,710 shares. The stock had previously closed at $154.31.

Several research analysts have recently commented on the company. BMO Capital Markets assumed coverage on Intercept Pharmaceuticals in a research report on Wednesday, April 6th. They issued an “outperform” rating for the company. Credit Suisse Group AG reiterated a “buy” rating and issued a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, April 7th. Wedbush reiterated an “outperform” rating and issued a $423.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, April 7th. Morgan Stanley lowered Intercept Pharmaceuticals from an “equal weight” rating to an “underperform” rating and decreased their target price for the stock from $100.00 to $80.00 in a research report on Friday, April 8th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, June 9th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $203.08.

The stock’s market cap is $3.64 billion. The company has a 50 day moving average price of $148.61 and a 200-day moving average price of $133.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($5.17) EPS for the quarter, missing the consensus estimate of ($3.60) by $1.57. During the same quarter in the previous year, the business earned ($1.78) earnings per share. On average, analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.82) earnings per share for the current fiscal year.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 714 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total value of $103,608.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lisa Bright sold 251 shares of the company’s stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the completion of the transaction, the insider now directly owns 18,855 shares of the company’s stock, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of ICPT. Rhumbline Advisers boosted its position in Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 109 shares during the period. ProShare Advisors LLC boosted its position in Intercept Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 20,213 shares of the biopharmaceutical company’s stock valued at $3,019,000 after buying an additional 1,130 shares during the period. California State Teachers Retirement System boosted its position in Intercept Pharmaceuticals by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,529 shares of the biopharmaceutical company’s stock valued at $4,410,000 after buying an additional 400 shares during the period. South Dakota Investment Council boosted its position in Intercept Pharmaceuticals by 6.8% in the fourth quarter. South Dakota Investment Council now owns 36,200 shares of the biopharmaceutical company’s stock valued at $5,406,000 after buying an additional 2,300 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock valued at $5,468,000 after buying an additional 578 shares during the period.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.